Content Hub
Blind Attendee List
Exclusive Speaker Interviews
Luca Biasco, VP of Translational Sciences, Nvelop Therapeutics
Having officially launched in April this year, Nvelop Therapeutics are developing two novel delivery platforms and applying these to cell-specific delivery of a broad set of therapeutic cargoes.
Listen to our interview with Luca, for insights into the current challenges facing in vivo delivery for the gene editing field, as well as his team’s key focus areas for 2025.
Marco Weinberg, Senior Vice President, Head of Research, ReCode Therapeutics
ReCode Therapeutics is a clinical-stage genetic medicines company developing and applying their selective organ targeting (SORT) lipid nanoparticle (LNP) delivery platform to mRNA and gene correction therapeutics and enable precise delivery to target organs and cells beyond the liver.
Read our interview with Marco for an insight into recent developments with applying SORT to extrahepatic indications, as well as his thoughts more broadly on recent developments in editing and delivery technologies within the gene therapy field.
Jeff Cehelsky, Vice President, Development Operations, Intellia Therapeutics
Intellia Therapeutics are a clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics that leverage CRISPR-based technologies.
Watch our exclusive interview to uncover the key challenges of translating exciting R&D into viable clinical programs, running gene editing clinical trials, and the importance of multistakeholder collaboration to progress the field.